| Dr Edward W Harmer, OD | |
|
43 Orchard St, Carteret, NJ 07008-1239 | |
| (732) 541-8222 | |
| (732) 541-0215 |
| Full Name | Dr Edward W Harmer |
|---|---|
| Gender | Male |
| Speciality | Optometry |
| Experience | 49 Years |
| Location | 43 Orchard St, Carteret, New Jersey |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1922105659 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | 27OA00356200 (New Jersey) | Primary |
| Provider Name | Omni Eye Specialists P A |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1376593863 PECOS PAC ID: 0547150062 Enrollment ID: O20040430000950 |
News Archive
Studying drugs in pediatric populations is challenging because drugs often affect children differently than they do adults. The scarcity of pediatric studies limits the ability of doctors and scientists to predict drug dosing, safety and efficacy in children. To address this gap, the National Institutes of Health announced today 18 grants to help determine outcome measures and increase the likelihood of success of future trials of treatments for children.
New research presented this week at ACR Convergence, the American College of Rheumatology's annual meeting, found that patients started on early, aggressive treatment with a combination of biologic and conventional disease modifying antirheumatic drugs (DMARDs) achieved clinically inactive disease in children with polyarticular juvenile idiopathic arthritis (JIA) more frequently compared to other treatment plans 24 months after starting treatment.
After 20 years of annual increases from 5 to 10 percent, rates for new cases of kidney failure have stabilized, according to new research from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). At the same time, dramatic racial disparities persist.
The Obama administration's surprise announcement will delay penalties for one year - until after the mid-term elections - and raises doubts about the implementation process at a crucial moment. Officials said the extension was a response to business requests for more time to navigate complex regulations.
Celladon Corp. announced today that the United States Patent and Trademark Office (USPTO) has granted a notice of allowance for a broad patent covering the company's lead drug candidate MYDICAR®, a genetically targeted enzyme replacement therapy for advanced heart failure. The patent will be issued to The Regents of the University of California and licensed exclusively to Celladon.
› Verified 4 days ago
| Provider Name | Carteret Eyecare Associates, Pc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1154519825 PECOS PAC ID: 0648367946 Enrollment ID: O20071102000576 |
News Archive
Studying drugs in pediatric populations is challenging because drugs often affect children differently than they do adults. The scarcity of pediatric studies limits the ability of doctors and scientists to predict drug dosing, safety and efficacy in children. To address this gap, the National Institutes of Health announced today 18 grants to help determine outcome measures and increase the likelihood of success of future trials of treatments for children.
New research presented this week at ACR Convergence, the American College of Rheumatology's annual meeting, found that patients started on early, aggressive treatment with a combination of biologic and conventional disease modifying antirheumatic drugs (DMARDs) achieved clinically inactive disease in children with polyarticular juvenile idiopathic arthritis (JIA) more frequently compared to other treatment plans 24 months after starting treatment.
After 20 years of annual increases from 5 to 10 percent, rates for new cases of kidney failure have stabilized, according to new research from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). At the same time, dramatic racial disparities persist.
The Obama administration's surprise announcement will delay penalties for one year - until after the mid-term elections - and raises doubts about the implementation process at a crucial moment. Officials said the extension was a response to business requests for more time to navigate complex regulations.
Celladon Corp. announced today that the United States Patent and Trademark Office (USPTO) has granted a notice of allowance for a broad patent covering the company's lead drug candidate MYDICAR®, a genetically targeted enzyme replacement therapy for advanced heart failure. The patent will be issued to The Regents of the University of California and licensed exclusively to Celladon.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Edward W Harmer, OD 43 Orchard St, Carteret, NJ 07008-1239 Ph: (732) 541-8222 | Dr Edward W Harmer, OD 43 Orchard St, Carteret, NJ 07008-1239 Ph: (732) 541-8222 |
News Archive
Studying drugs in pediatric populations is challenging because drugs often affect children differently than they do adults. The scarcity of pediatric studies limits the ability of doctors and scientists to predict drug dosing, safety and efficacy in children. To address this gap, the National Institutes of Health announced today 18 grants to help determine outcome measures and increase the likelihood of success of future trials of treatments for children.
New research presented this week at ACR Convergence, the American College of Rheumatology's annual meeting, found that patients started on early, aggressive treatment with a combination of biologic and conventional disease modifying antirheumatic drugs (DMARDs) achieved clinically inactive disease in children with polyarticular juvenile idiopathic arthritis (JIA) more frequently compared to other treatment plans 24 months after starting treatment.
After 20 years of annual increases from 5 to 10 percent, rates for new cases of kidney failure have stabilized, according to new research from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). At the same time, dramatic racial disparities persist.
The Obama administration's surprise announcement will delay penalties for one year - until after the mid-term elections - and raises doubts about the implementation process at a crucial moment. Officials said the extension was a response to business requests for more time to navigate complex regulations.
Celladon Corp. announced today that the United States Patent and Trademark Office (USPTO) has granted a notice of allowance for a broad patent covering the company's lead drug candidate MYDICAR®, a genetically targeted enzyme replacement therapy for advanced heart failure. The patent will be issued to The Regents of the University of California and licensed exclusively to Celladon.
› Verified 4 days ago
Carteret Eyecare Associates, Pc Optometrist Medicare: Medicare Enrolled Practice Location: 43 Orchard St, Carteret, NJ 07008 Phone: 732-541-8222 Fax: 732-541-0215 | |
Advanced Eyecare Of Carteret Inc Optometrist Medicare: Medicare Enrolled Practice Location: 29 Washington Ave Unit 107, Carteret, NJ 07008 Phone: 610-653-8849 |